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The ABCC6 gene encodes MRP6, a member of the multidrug resistance-associated protein (MRP) family. Interest in
ABCC6/MRP6 derives, in part, from the fact that mutations in this gene/protein system have been identiﬁed in
families with pseudoxanthoma elasticum (PXE). Early studies indicated that ABCC6 is expressed primarily in the
liver and to a lesser extent in the kidney, but more recently a widespread distribution has been suggested. To
explore the tissue-specific expression of ABCC6, we ﬁrst examined various mouse tissues by RT-PCR. The results
indicated high levels of mRNA in the liver, whereas low level of expression was noted in the kidney and small
intestine. To explore other tissues in which initial RT-PCR was essentially negative, a second-round nested PCR
was performed, which revealed expression also in the brain, tongue, stomach, and eye. Unexpectedly, however,
distinct PCR products of smaller molecular weight were noted in these tissues. Subcloning and sequencing of
these PCR products indicated that they reﬂected aberrant splicing in the 30 end of the ABCC6 mRNA, resulting in
each case in a premature termination codon. Similar results were noted with RT-PCR analysis using RNA isolated
from cultured human epidermal keratinocytes and dermal ﬁbroblasts. Collectively, our results conﬁrm high level of
expression of ABCC6 in the liver and the kidney, whereas very low level of expression in a variety of other tissues
was noted. The results have implications for mutation detection strategies in PXE by RT-PCR, and they further
support the notion that PXE is a primary metabolic disorder.
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ABCC6 belongs to the family of genes encoding proteins
with an ATP-binding cassette, and this gene specifically
encodes MRP6, a member of the family of multidrug re-
sistance-associated proteins (MRP) (Borst et al, 1999). Al-
though the precise physiologic function of MRP6 is currently
unknown, it is thought to be a transmembrane transporter
due to its high degree (  41%) homology with the proto-
type protein, MRP1, an efflux transporter expressed in the
liver (Belinsky and Kruh, 1999; Kool et al, 1999). The se-
quence information derived from full-length ABCC6 cDNA
and from genomic sequences predicts that MRP6 consists
of 1503 amino acids, characterized by the presence of three
membrane spanning domains (MSD1-3), comprising 5, 6,
and 6 transmembrane segments, respectively (for review,
see Uitto et al, 2001). MRP6, in analogy to other ABC
transporter proteins, has two intracellular nucleotide bind-
ing folds (NBF1, NBF2), each domain containing conserved
Walker A and B motifs critical for ATP binding and the
function of the protein as a transmembrane transporter. The
ABCC6 gene consists of 31 exons spanning  73 kb of
DNA on the short-arm of human chromosome 16, at locus
16p13.1. The corresponding mRNA is  6 kb in size, and it
has an open reading frame of 4.5 kb.
The interest in the ABCC6/MRP6 gene/protein system
has been heightened by the discovery that mutations in the
ABCC6 gene underlie pseudoxanthoma elasticum (PXE), a
heritable systemic disorder affecting elastic structures in the
skin, eyes, and the cardiovascular system (see Ringpfeil
et al, 2000, 2001a; Le Saux et al, 2001). The extent of
ABCC6 expression in various tissues has been controver-
sial. During early characterization of ABCC6 by northern
analysis, it was suggested that this gene is expressed pre-
dominantly in the liver and to a lesser extent in the kidney,
whereas a number of other tissues tested were essentially
devoid of the corresponding mRNA transcript (Belinsky and
Kruh, 1999). This and related observations led us to con-
clude that PXE may be primarily a metabolic disorder re-
sulting from the lack of activity of MRP6 as a putative
transmembrane transporter in the liver (Uitto et al, 2001). At
the same time, highly sensitive RNase protection assays
(Kool et al, 1999) and RT-PCR (Bergen et al, 2000) sug-
gested that ABCC6 mRNA may be present in other tissues
as well, albeit in much lower abundance, including the skin,
the eye, and the vessel wall, i.e., sites of pathology in PXE.
Furthermore, a combination of RNase protection assays, in
vitro hybridization, and immunohistochemical analyses dem-
onstrated the presence of MRP6 not only in epithelial and
endothelial cells in a variety of tissues but also in neurons
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and leukocytes (Beck et al, 2003). These observations sug-
gested a more complex multifunctional role for ABCC6 and
further implied that perturbations in the physiology of local
cellular milieu in the absence of MRP6 activity may mech-
anistically contribute to the pathogenesis of PXE.
To address the controversy regarding the tissue-specific
expression of the ABCC6 gene, this study was designed to
define the expression profile of this gene. Specifically, we
have examined various mouse tissues and different cell
types by a highly sensitive two-step PCR strategy consist-
ing of first-step RT-PCR, followed by a second-step nested
PCR. Our results confirm that the ABCC6 gene is expressed
predominantly in the liver and the kidney, but low level
of expression can also be observed in a variety of other
tissues. The low level of expression, however, in several
tissues is accompanied by extensive aberrant splicing, par-
ticularly in the 30 end of the mRNA, and many of these
transcripts predict the synthesis of non-functional MRP6
polypeptides.
Results
ABCC6 mRNA abundance in the mouse liver and the
kidney The ABCC6 gene has been shown, on the basis of
Northern analysis (Belinsky and Kruh, 1999), to be expressed
predominantly in the liver and the kidney, but more wide-
spread tissue distribution has also been reported by more
sensitive techniques (Kool et al, 1999; Beck et al, 2003). In
this study, we examined ABCC6 gene expression profile in a
variety of mouse tissues by a highly sensitive two-step PCR
strategy, consisting of the first-step RT-PCR and followed by
a second-step nested PCR. We first isolated total RNA from
several mouse tissues and subjected to RT-PCR with primers
corresponding to exon 22 (forward primer) and the 30-un-
translated sequence within exon 31 (reverse primer) (see
Table S1). After 30 cycles of amplification, a clear band of the
expected size,  1.7 kb, could be noted with RNA isolated
from the liver and to a lesser degree in the kidney (Fig 1A). A
faint band was also noted with RNA isolated from the small
intestine, whereas the remaining tissues, including the
skin and the eye, were essentially negative. Amplification
of glyceraldehyde-3-phosphatede hydrogenase (GAPDH) se-
quences using the same RNA preparations as templates re-
vealed the presence of a band of approximately equal
intensity in all samples, attesting to the presence and integ-
rity of mRNA in these specimens (Fig 1A).
Evidence for very low level of expression of ABCC6 in a
number of mouse tissues To pursue further the expres-
sion of ABCC6 in tissues that showed low or undetectable
levels of mRNA abundance by the first-round RT-PCR, an
aliquot of the first-round product was subjected to a second
round of amplification using nested primers within exons 23
and 31 (see Fig 2, top panel). After an additional 30 cycles,
bands of the expected size,  1.5 kb, were noted in the
kidney, brain, small intestine, stomach and eye, however, no
signal was obtained from the skin RNA (Fig 1B). In addition
to the band of the expected size, additional bands of small-
er molecular mass were noted in the brain, stomach and
eye (Fig 1B). Furthermore, tongue mRNA resulted in a single
PCR product, which was smaller than expected (  1.2 kb).
Aberrant splicing in the 30-end of the mouse mRNA The
products that were smaller than expected from the second
round nested PCR (1.5 kb) were subcloned and subjected
to automated sequencing. Sequence comparison of the
products with full-length ABCC6 mRNA sequence, as ob-
tained using liver mRNA as template and validated by the
genomic sequences, revealed that these bands represented
aberrantly spliced mRNA transcripts (Fig 2). The smaller
band obtained from brain mRNA was clearly devoid of ex-
ons 24–29, whereas tongue mRNA yielded a PCR product
missing exons 27–29. Similarly, the small intestine had a
weak band representing a PCR product devoid of exons
24–29, and in case of stomach mRNA, the predominant
band was devoid of exons 25–29 but contained an insertion
of 75 nucleotides representing intron 29 sequences (Fig 2).
Finally, eye mRNA, in addition to the PCR products of the
expected size, had three different products devoid of exons
28 and 29, 25–27, and 25–29, respectively. All these dele-
tions are expected to affect the function of MRP6, as they
predict deletion of sequences within the NBF2, a critical
functional component of the protein, which is encoded by
exons 28–30 (Fig 2, top panel). Furthermore, all the ob-
served deletions are out-of-frame and are predicted to re-
sult in premature termination codon (PTC) of translation, in
most cases within the 50 end of exon 31 encoding the C-
terminal end (CT) of the protein (Fig 2).
Low level of expression and aberrant splicing of the
ABCC6 mRNA in human skin cells To examine whether
similar aberrant splicing could be observed in human cells
as well, RT-PCR was performed on total RNA isolated from
cultured epidermal keratinocytes and dermal fibroblasts,
Figure1
Expression of the ABCC6 gene in various mouse tissues. (A) RT-
PCR was performed using total RNA (1 mg) isolated from various mouse
tissues (liver, kidney, skin, brain, tongue, small intestine, stomach, and
eye) as template. Amplification with the ABCC6 specific primer pair
(see Table S1) was shown to result in a fragment of the expected size,
 1.7 kb (arrow), encoding exons 22–31, in the liver, kidney and small
intestine (upper panel). Glyceraldehyde-3-phosphatede hydrogenase
mRNA was amplified as a control to ensure the presence and integrity
of mRNA (lower panel). (B) Nested PCR was carried out using 1 mL of
each PCR product from the first-round RT-PCR. Amplification with the
nested primer pair resulted in a product of the expected size,  1.5 kb
(arrow), encoding exons 23–31. In addition, bands smaller than ex-
pected were noted in several tissues (arrowheads).
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the two principal cell types present in the skin. Initial am-
plification utilizing primers within exons 23 and 31 revealed
no distinct bands with 30 cycles of amplification (not
shown). Utilization of nested primers in second-round
PCR covering segments spanning exons 23–26, 25–29,
and 29–31, however, resulted in distinct bands, some of
them being smaller than expected from the full size PCR
product (Fig 3). Specifically, subcloning and sequencing of
the keratinocyte-derived PCR products revealed the ab-
sence of exons 24 and 30, whereas in case of fibroblasts
deletion of exons 24, 26, and 28 was noted. In case of both
keratinocyte and fibroblast PCR products, a PTC for trans-
lation was predicted within exon 27 (Fig 3). Thus, although
ABCC6 mRNA sequences can be detected both in epider-
mal keratinocytes and in dermal fibroblasts by nested sec-
ond round PCR, indicating a very low level of expression,
sequence analysis of the PCR products suggests the pres-
ence of predominantly truncated mRNA species, which are
predicted to result in the synthesis of non-functional MRP6
protein.
Similar RT-PCR analyses for detection of possible alter-
native splicing in the 50 region (exons 1–22) of the ABCC6
mRNA in human epidermal keratinocytes and dermal fibro-
blasts were also performed. In fibroblasts, a minor PCR
product representing alternatively spliced exon 7 was not-
ed, whereas no evidence for aberrant splicing affecting the
remaining exons (1–6 and 8–22) was obtained (not shown).
Furthermore, no evidence for alternative splicing affecting
exons 1–23 was obtained with keratinocyte RNA. Thus, the
alternative splicing in case of ABCC6 mRNA is limited es-
sentially to the 30 end of the transcript.
Discussion
PXE is a heritable disorder with characteristic phenotypic
manifestations in the skin, the eyes, and the cardiovascular
system (Neldner, 1988; Uitto and Pulkkinen, 2002). The
unifying pathologic feature in these three principal tissues
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Figure 2
Aberrant splicing affects the 30-end of the mouse ABCC6 gene.
Bands smaller than expected in the second-round nested PCR (see Fig
1) were subcloned and subjected to automated sequencing, which re-
vealed aberrant splicing in tissues as indicated. Schematic represen-
tation shown on the top depicts exons 23–31 (open boxes) resulting
from normal splicing. This segment of the mRNA encodes the third
membrane spanning domain (MSD3, exons 23–27), the second nuc-
leotide binding fold (NBF2, exons 28–30), and the C-terminal end of the
polypeptide (CT, partial exon 31) and contains the 30-untranslated re-
gion (30-UTR). The positions of the primer pair mE23F and mE31R2
used in the nested PCR (short arrows) and the natural termination co-
don (TGA, open arrowhead) are shown. The regions of aberrant splicing
are shown as solid vertical bars between exons, and positions of pre-
mature termination codons (PTC) are marked by solid arrowheads.
Smaller, and predominant, PCR products in stomach mRNA included
partial sequences of intron 29 (striped box) containing a PTC.
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Figure3
Expression and aberrant splicing of the human ABCC6 gene in
cultured keratinocytes and fibroblasts. (A) Nested PCR was per-
formed using 1 ml of the first-round RT-PCR products obtained with
total RNA from the cultured human epidermal keratinocytes and dermal
fibroblasts as templates. Amplification with the nested primer pairs
(E23U and E26L, E25F and E29L, and E29F and E31L, see Table S1)
resulted in bands of the expected size (arrows) as well as in bands that
were smaller than expected (arrowheads). (B) The smaller bands were
subcloned and subjected to automated sequencing, which showed
aberrant splicing in both types of cultured cells. Schematic represen-
tation indicates the wild-type sequence of exons 23–31 (WT, open
boxes) reflecting normal splicing. The positions of the nested primer
pairs (arrows), the natural termination codon (TGA, open arrowhead),
and premature termination codons in exon 27 due to aberrant splicing
(solid arrowheads) are indicated. The regions of aberrant splicing are
shown as solid bars between the exons.
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affected in PXE is accumulation of abnormal elastic struc-
tures with aberrant mineralization. Based on these obser-
vations, PXE was originally thought to be a heritable
connective tissue disease with primary abnormalities in
elastin or associated microfibrillar components of the elastic
structures (McKusick, 1972). Analyses of the candidate
genes, including elastin on chromosome 7, and several
components of the elastin associated microfibrils on chro-
mosomes 5 and 15, however, were unyielding (see Ringpfeil
et al, 2001b). Subsequently, positional cloning approaches
localized the gene mutated in PXE to chromosomal region
16p13.1 (Le Saux et al, 1999; Cai et al, 2000), and se-
quencing of the candidate genes within the critical interval
revealed mutations in the ABCC6 gene, a member of the
ATP-binding cassette family of genes (Bergen et al, 2000; Le
Saux et al, 2000; Ringpfeil et al, 2000; Struk et al, 2000). The
protein known as MRP6 was initially included in the MRP
family due to its structural homology with MRP1, a well-
characterized transmembrane efflux pump primarily trans-
porting amphipathic anionic conjugates, such as glutathi-
one-S conjugates as well as glucuronidated and sulfated
compounds (Borst et al, 1999). On the basis of structural
homology, it was suggested that the function of MRP6
could also relate to cellular detoxification.
MRP6 consists of 1,503 amino acids, the primary se-
quence predicting the presence of three membrane span-
ning domains (MSD1-3) and two NBF (NBF1, NBF2). The
membrane spanning domains are essential for proper top-
ographic insertion of the protein into the plasma membrane,
and NBF’s play a critical role for MRP6 to serve as a pu-
tative metabolic transporter. Most of the mutations encoun-
tered in families with PXE consist of PTC, due to nonsense
mutations or out-of-frame insertions or deletions, or of mis-
sense mutations affecting critical amino acid residues either
within the NBF2 or in the intracellular peptide segment
connecting two transmembrane segments within MSD3
(see Le Saux et al, 2001; Ringpfeil et al, 2001a; Uitto et al,
2001). These mutations are predicted to result in inactiva-
tion of the putative function of MRP6. Interestingly, all mu-
tations characterized thus far are recessive, and inactivation
of both alleles of the ABCC6 gene is required for clinical
phenotype.
Considering the multi-system nature of PXE, a surprising
finding was that the ABCC6 gene was expressed in high
abundance in the liver and to a lesser extent in the kidney. In
fact, northern hybridizations with RNA from a number of
other human tissues, besides liver and kidney, failed to find
expression (Belinsky and Kruh, 1999). This and related ob-
servations led us to suggest that PXE may be primarily a
metabolic disorder at the environment-genome interface,
and that absence of MRP6 activity in the liver may result in
metabolic perturbation that facilitates calcification of elastic
structures in the target tissues (Uitto et al, 2001). In support
of this interpretation were the clinical observations that PXE,
even though clearly a heritable disorder with high degree of
penetrance, is not present at birth or during the early child-
hood, but the diagnosis is established usually in mid to late
teens (Neldner, 1988). Furthermore, the disease is slowly
progressing, consistent with accumulation of a noxious
metabolite(s). At the same time, more sensitive analyses
using RT-PCR and RNA protection assays have suggested
more wide-spread tissue expression of the ABCC6 gene,
including the presence of the corresponding mRNA tran-
scripts in the skin and vessel wall, in skin fibroblasts and in
neural tissues and leukocytes (Bergen et al, 2000; Le Saux
et al, 2000; Beck et al, 2003). These observations have
led to the suggestion that the ABCC6/MRP6 gene/protein
system may play a role in protecting the extracellular milieu
against oxidative stress by serving as a transporter of
free radical scavengers in the local microenvironment of
the skin, the eye, and the vessel wall. In the absence
of MRP6 transport activity, oxidative stress damages the
connective tissue and promotes calcification. This sugges-
tion is based on the observation that one of the substrates
transported by MRP6 in in vitro systems is glutathione
conjugated to leukotriene C4 and N-ethylmaleimide, an
established free radical quencher (Belinsky et al, 2002;
Ilia´s et al, 2002).
Considering the uncertainty regarding the molecular
mechanisms involved in development of PXE phenotype
at tissue level as a result of ABCC6 mutations, we sought to
clarify the tissue expression profile of ABCC6. Our results,
obtained by an exquisitely sensitive two-step PCR strategy,
clearly demonstrate that liver is the predominant site of
expression of this gene, with lower levels of the ABCC6
mRNA in the kidney and small intestine. These data agree
with previous observations obtained by using northern
analysis and mRNA protection assays (Belinsky and Kruh,
1999; Kool et al, 1999). Using the sensitive second-round
PCR we were able to show expression of ABCC6 in a
number of additional tissues, yet the expression was ex-
tremely low. A surprising finding in tissues expressing
ABCC6 at very low levels was the presence of mRNA tran-
scripts that were shown to reflect aberrant splicing, partic-
ularly in the 30 end of the mouse mRNA affecting the region
corresponding to exons 23–31. In some instances, the ab-
errantly spliced variant was the exclusive (tongue) or pre-
dominant (stomach) species of mRNA. Detailed analysis
of the splice variants by subcloning and nucleotide se-
quencing revealed that the deleted exons encode segments
of MSD3 or NBF2, domains critical for the function of
MRP6 as a putative transmembrane transporter. Further-
more in each case, the deletions were out-of-frame, causing
generation of missense sequences and a PTC. Thus, the
protein translation products generated from the aberrantly
spliced mRNAs are predicted to result in synthesis of a non-
functional protein.
Tissue-specific expression of genes is the basic mech-
anism of development and differentiation in multicellular
eukaryotes. Therefore, genes can be classified into either
tissue-specific or housekeeping genes. The tissue-specific
genes encode proteins involved in functional and pheno-
typic characteristics of a cell type, and consequently, tran-
scripts of tissue-specific genes are considered to exist only
in the corresponding tissues. We show in this study that a
highly tissue-specific gene, ABCC6, which is primarily ex-
pressed in the liver, is also expressed as spliced transcripts
in nonspecific tissues. This finding is consistent with the
suggestion that any gene may be transcribed at a very low
level in any cell type (Chelly et al, 1989). In addition, since
aberrant RNA splicing is observed in a high proportion of
genes, it is not surprising that alterations in RNA splicing
ABCC6 GENE EXPRESSION 903125 : 5 NOVEMBER 2005
can cause or be associated by a disease (Faustino et al,
2003). Finally, it should be emphasized that the expression
of the ABCC6 gene, in tissues other than liver, kidney, and
the intestine, as determined at the mRNA level, is extremely
low and may well represent illegitimate transcription (Chelly
et al, 1989). Thus, the extremely low level of expression,
combined with demonstration of transcripts predicting syn-
thesis of non-functional protein, all emphasize the point that
ABCC6 is expressed predominantly, if not exclusively, in the
liver and the kidney.
Examination of cultured epidermal keratinocytes and
dermal fibroblasts established from human skin revealed
the presence of similar aberrant splicing within the 30 end of
the ABCC6 mRNA corresponding to exons 23–31. It should
be noted that cultured keratinocytes did not express exon
24, whereas a previous study (Bergen et al, 2000) was able
to amplify ABCC6 mRNA segments in the skin with an exon
24-specific primer. One explanation for this difference is
that cultured keratinocytes might not fully reflect the gene
expression spectrum of skin. Alternatively, skin contains a
number of other cell types besides keratinocytes, which
could contain transcripts retaining exon 24. Again, critical
exons encoding MSD3 and NBF2 segments were deleted,
and the deletions resulted in a PTC within exon 27 predict-
ing synthesis of a non-functional protein. It is of interest that
similar analysis of the remaining 50-segment of the mRNA,
exons 1–23, did not reveal evidence of significant level
of aberrant splicing in keratinocytes or fibroblasts. The
reasons for the concentration of aberrant splicing to the 30
end of the mRNA are not clear. There is a possibility, how-
ever, that aberrant splicing within the exons 1–23 of the
transcript may generate PTCs which, when present in the 50
segment of the mRNA, result in rapid loss of the corre-
sponding mRNA transcripts through nonsense mediated
mRNA decay (Vasudevan et al, 2002). The aberrantly
spliced transcripts may not be present to serve as tem-
plate for RT-PCR, provided that the nonsense mediated
decay is exceptionally rapid.
The results presented in this study may complicate mo-
lecular diagnostics of PXE. First, mutation detection strate-
gies have been developed to identify pathogenetic lesions
in the ABCC6 gene, and a large number of such mutations
have been identified using genomic DNA as a template for
PCR amplification (see Le Saux et al, 2001; Ringpfeil et al,
2001b). It should be noted that such analyses have been
complicated by the presence of at least two pseudogenes
which harbor sequences corresponding to exons 1–9 of
the authentic ABCC6 (Pulkkinen et al, 2001). It has been
suggested that this complication could be avoided by utiliz-
ing RT-PCR for mutation detection with RNA as template.
Demonstration of extensive aberrant splicing may, however,
complicate mutation detection using mRNA as a template.
Secondly, our findings that ABCC6 is expressed in high
abundance in the liver, as previously demonstrated by others
(Belinsky and Kruh, 1999; Kool et al, 1999), to a lesser extent
in the kidney, and at very low level in the remaining tissues
tested, further lend support to the notion of PXE as a met-
abolic disorder. Even though low level of expression can be
found in a number of other tissues, and shown in our study
also in cultured keratinocytes and fibroblasts, the two prin-
cipal cell types in human skin, the predominant species of
ABCC6 mRNA in these cells are aberrantly spliced predicting
the synthesis of non-functional protein. It is conceivable,
therefore, that the absence of MRP6 in the liver in
patients with PXE results in metabolic perturbation which
phenotypically affects the target tissues rich in elastic
structures.
Materials and Methods
Cell culture Human epidermal keratinocytes were isolated from
neonatal foreskin and grown in serum-free keratinocyte growth
medium (KGM, Clontec, San Diego, California) as described
previously (Tamai et al, 1995). Human dermal fibroblasts were iso-
lated from same tissue specimens and maintained in Dulbecco’s
modified Eagle’s medium supplemented with heat-inactivated
fetal calf serum, 2 mM L-glutamine, 100 IU per mL penicillin,
and 100 mg per mL streptomycin (Cellgro, Mediatech, Herndon,
Virginia).
The use of human tissues was approved by Thomas Jefferson
University Institutional Review Board, and all experiments adhere
to the principles of Helsinki Declaration Guidelines.
RT-PCR Eight-wk-old male C57BL/6 mice were sacrificed by CO2
asphyxiation and tissues were immediately excised and homog-
enized in 1 mL TRIzol reagent (Invitrogen, Carlsbad, California) per
100 mg tissue. Total RNA was isolated from these tissues, as well
as from cultured epidermal keratinocytes and dermal fibroblasts,
using the TRIzol reagent, as recommended by the manufacturer.
First-strand cDNA synthesis was performed by the use of 1 mg total
RNA, oligo(dT) primer (Promega, Madison, Wisconsin), and Su-
perscript II reverse transcriptase (Invitrogen), according to the
manufacturers’ instructions.
Cloning of the 30-end of the ABCC6 cDNA Sequences of the
primer pairs used to detect the mouse exons 22–31 transcripts
(mE22F and mE31R, first-round RT-PCR), the mouse exons 23–31
sequences (mE23F and mE31R2, second round nested PCR), the
human exons 23–31 (E23F and E31R, first-round RT- PCR), and the
human exons 23–26 (E23U and E26L), exons 25–29 (E25F and
E29L), and exons 29–31 (E29F and E31L) sequences (all for sec-
ond-round nested PCR), as well as the primers used for amplifi-
cation of GAPDH as a control, are shown in Table S1. The
annealing temperatures of PCR primers and the expected sizes of
the products are also listed in Table S1. A 25 ml PCR reaction
mixture consisted of 1  PCR buffer, 1  Q-buffer, 1.25 U Taq
polymerase (Qiagen, Valencia, California), 200 mM nucleotide mix,
15 pmol each primer, and 1 ml each first-strand cDNA. The am-
plification conditions were 941C for 5 min, followed by 30 cycles of
(941C for 45 s, the annealing temperature (52–601C; see Table S1)
for 45 s, and 721C for 2 min), and one cycle of 721C for 10 min.
Second-round nested PCR was performed using 1 ml each PCR
product from the first-round RT-PCR as template. The PCR prod-
ucts were separated by gel electrophoresis on 1.5% agarose gels
and stained with ethidium bromide. The products were cloned into
the pCR4-TOPO vector as recommended by the manufacturer
(Invitrogen). Recombinant plasmids were purified with the Miniprep
Kit (Qiagen) and subjected to nucleotide sequence analysis using
ABI 377 DNA sequencer.
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The following material is available online for this article.
Table S1 Primers used in ﬁrst-round RT-PCR and in second-round nested
PCR of ABCC6 mRNA
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